KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Liabilities (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Other Non-Current Liabilities readings, the most recent being $8.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a N/A change, with the full-year FY2025 number at $8.7 million, changed N/A from a year prior.
  • Other Non-Current Liabilities hit $8.7 million in Q4 2025 for Esperion Therapeutics, up from $7.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $265.0 million in Q3 2022 to a low of $1.3 million in Q3 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $228.1 million (2021), compared with a mean of $176.9 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 99.19% in 2021 and later surged 20446.36% in 2022.
  • Esperion Therapeutics' Other Non-Current Liabilities stood at $245.7 million in 2021, then decreased by 10.95% to $218.8 million in 2022, then rose by 9.64% to $240.0 million in 2023, then decreased by 1.48% to $236.4 million in 2024, then tumbled by 96.3% to $8.7 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $8.7 million (Q4 2025), $7.4 million (Q3 2025), and $7.4 million (Q2 2025) per Business Quant data.